Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients

Benton Ng, Anne Dipchand, David Naftel, Paolo Rusconi, Gerard Boyle, Theo Zaoutis, R. Erik Edens

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PJP is known to cause significant morbidity and rarely death in immunosuppressed patients. The prevalence and outcomes of PJP in pediatric solid-organ transplant patients are not well established. This study utilizes data from the PHTS to establish the prevalence and outcome of PJP in pediatric heart transplant recipients. We conducted a retrospective cohort study using data from the PHTS, including data from 24 institutions between January 1, 1993, and December 31, 2004. Infections that occur in PHTS subjects are recorded in a standardized data collection form. The prevalence and outcomes of PJP in pediatric heart transplant recipients were determined. There were a total of 18 patients (1%) with PJP out of the 1854 pediatric heart transplant recipients in the PHTS database. A majority of PJP occurred two months to two yr post-transplant, and patients with PJP had a significantly decreased mortality compared with other fungal infections. PJP is an infrequent complication experienced by pediatric heart transplant recipients. Patients that have experienced PJP have an increased survival compared to patients with other fungal infections, and most PJP occurred within two yr of transplant.

Original languageEnglish
Pages (from-to)844-848
Number of pages5
JournalPediatric Transplantation
Volume15
Issue number8
DOIs
StatePublished - Dec 1 2011

Fingerprint

Pneumocystis carinii
Pneumocystis Pneumonia
Pediatrics
Infection
Mycoses
Transplants
Transplant Recipients
Cohort Studies
Retrospective Studies
Databases
Morbidity
Survival
Mortality

Keywords

  • heart
  • infection
  • pediatric
  • Pneumocystis jiroveci
  • transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients. / Ng, Benton; Dipchand, Anne; Naftel, David; Rusconi, Paolo; Boyle, Gerard; Zaoutis, Theo; Edens, R. Erik.

In: Pediatric Transplantation, Vol. 15, No. 8, 01.12.2011, p. 844-848.

Research output: Contribution to journalArticle

Ng, Benton ; Dipchand, Anne ; Naftel, David ; Rusconi, Paolo ; Boyle, Gerard ; Zaoutis, Theo ; Edens, R. Erik. / Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients. In: Pediatric Transplantation. 2011 ; Vol. 15, No. 8. pp. 844-848.
@article{d0400783f98e466d8d96d2515d4a8bbc,
title = "Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients",
abstract = "PJP is known to cause significant morbidity and rarely death in immunosuppressed patients. The prevalence and outcomes of PJP in pediatric solid-organ transplant patients are not well established. This study utilizes data from the PHTS to establish the prevalence and outcome of PJP in pediatric heart transplant recipients. We conducted a retrospective cohort study using data from the PHTS, including data from 24 institutions between January 1, 1993, and December 31, 2004. Infections that occur in PHTS subjects are recorded in a standardized data collection form. The prevalence and outcomes of PJP in pediatric heart transplant recipients were determined. There were a total of 18 patients (1{\%}) with PJP out of the 1854 pediatric heart transplant recipients in the PHTS database. A majority of PJP occurred two months to two yr post-transplant, and patients with PJP had a significantly decreased mortality compared with other fungal infections. PJP is an infrequent complication experienced by pediatric heart transplant recipients. Patients that have experienced PJP have an increased survival compared to patients with other fungal infections, and most PJP occurred within two yr of transplant.",
keywords = "heart, infection, pediatric, Pneumocystis jiroveci, transplantation",
author = "Benton Ng and Anne Dipchand and David Naftel and Paolo Rusconi and Gerard Boyle and Theo Zaoutis and Edens, {R. Erik}",
year = "2011",
month = "12",
day = "1",
doi = "10.1111/j.1399-3046.2011.01589.x",
language = "English",
volume = "15",
pages = "844--848",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients

AU - Ng, Benton

AU - Dipchand, Anne

AU - Naftel, David

AU - Rusconi, Paolo

AU - Boyle, Gerard

AU - Zaoutis, Theo

AU - Edens, R. Erik

PY - 2011/12/1

Y1 - 2011/12/1

N2 - PJP is known to cause significant morbidity and rarely death in immunosuppressed patients. The prevalence and outcomes of PJP in pediatric solid-organ transplant patients are not well established. This study utilizes data from the PHTS to establish the prevalence and outcome of PJP in pediatric heart transplant recipients. We conducted a retrospective cohort study using data from the PHTS, including data from 24 institutions between January 1, 1993, and December 31, 2004. Infections that occur in PHTS subjects are recorded in a standardized data collection form. The prevalence and outcomes of PJP in pediatric heart transplant recipients were determined. There were a total of 18 patients (1%) with PJP out of the 1854 pediatric heart transplant recipients in the PHTS database. A majority of PJP occurred two months to two yr post-transplant, and patients with PJP had a significantly decreased mortality compared with other fungal infections. PJP is an infrequent complication experienced by pediatric heart transplant recipients. Patients that have experienced PJP have an increased survival compared to patients with other fungal infections, and most PJP occurred within two yr of transplant.

AB - PJP is known to cause significant morbidity and rarely death in immunosuppressed patients. The prevalence and outcomes of PJP in pediatric solid-organ transplant patients are not well established. This study utilizes data from the PHTS to establish the prevalence and outcome of PJP in pediatric heart transplant recipients. We conducted a retrospective cohort study using data from the PHTS, including data from 24 institutions between January 1, 1993, and December 31, 2004. Infections that occur in PHTS subjects are recorded in a standardized data collection form. The prevalence and outcomes of PJP in pediatric heart transplant recipients were determined. There were a total of 18 patients (1%) with PJP out of the 1854 pediatric heart transplant recipients in the PHTS database. A majority of PJP occurred two months to two yr post-transplant, and patients with PJP had a significantly decreased mortality compared with other fungal infections. PJP is an infrequent complication experienced by pediatric heart transplant recipients. Patients that have experienced PJP have an increased survival compared to patients with other fungal infections, and most PJP occurred within two yr of transplant.

KW - heart

KW - infection

KW - pediatric

KW - Pneumocystis jiroveci

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=82155191364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155191364&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2011.01589.x

DO - 10.1111/j.1399-3046.2011.01589.x

M3 - Article

VL - 15

SP - 844

EP - 848

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 8

ER -